SEC 13F Intelligence

Managers / Q3 2020 · view latest →

Birchview Capital, LP

CIK 0001618205 · 688 PINE STREET, SUITE D, C/O BIRCHVIEW CAPITAL, BURLINGTON, VT, 05401 · 802-923-3826

Reported Value
$150M
Q3 2020
Positions
50
Filings on Record
39
2019–present window
Filed
Nov 12, 2020
amendment (RESTATEMENT)

Summary

Birchview Capital, LP reported $150M in U.S.-listed holdings across 50 positions for Q3 2020.

The portfolio is heavily concentrated: BMY alone accounts for 32.0% of reported value.

Compared with Q2 2020, the fund opened 0 new positions and exited 1.

Portfolio Metrics

Turnover
+3.6%
vs prior filed quarter
Top-10 Concentration
+78.1%
share of reported value
Largest Position
+32.0%
Bristol Myers Squibb

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $106MQ4 ’18Q1 ’19: $160MQ2 ’19: $164MQ3 ’19: $150MQ4 ’19: $138MQ4 ’19Q1 ’20: $113MQ2 ’20: $165MQ3 ’20: $150MQ4 ’20: $174MQ4 ’20Q1 ’21: $168MQ2 ’21: $167MQ3 ’21: $147MQ4 ’21: $155MQ4 ’21Q1 ’22: $139MQ2 ’22: $137MQ3 ’22: $142MQ1 ’23: $127,725Q1 ’23Q3 ’23: $117MQ4 ’23: $128MQ1 ’24: $122MQ2 ’24: $108MQ2 ’24Q3 ’24: $115MQ4 ’24: $123MQ1 ’25: $115MQ2 ’25: $101MQ2 ’25Q3 ’25: $132MQ4 ’25: $171MQ1 ’26: $176Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 69.3%Other: 28.9%Right: 1.8%
  • Common Stock · 69.3% · $104M
  • Other · 28.9% · $43M
  • Right · 1.8% · $3M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2020 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
GILDGILEAD SCIENCES INCSOLD OUT−10.0K0−$769,000$0
BMY-RBMY CVR RTS 03/31/21ADDED+500.0K1.21M+$184,000$3M
WKHSEURWORKHORSE GROUP INCTRIMMED−7.0K8.0K−$59,000$202,000
INARI MEDICAL INCTRIMMED−3.0K7.0K−$1,000$483,000
BDQMALBIREO PHARMA INCADDED+10.0K58.0K+$663,000$2M
AMARIN CORP PLCADDED+40.0K300.0K−$536,000$1M
QDEL*QUIDEL CORPADDED+7.7K58.6K+$1M$13M
ACADACADIA PHARMACEUTICALS INCADDED+9.0K102.0K−$300,000$4M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2020

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1BMYBRISTOL-MYERS SQUIBB COhistory →COM32.00%$48M794.4K
2ACCELERATE DIAGNOSTICS INCCOM15.62%$23M2.19M
3QDEL*QUIDEL CORPhistory →COM8.60%$13M58.6K
4ASPIRA WOMENS HEALTH INCCOM6.36%$10M3.09M
5NBIXNEUROCRINE BIOSCIENCES INChistory →COM5.01%$8M78.0K
6ACADACADIA PHARMACEUTICALS INChistory →COM2.81%$4M102.0K
7BLUEBIRD BIO INCCOM2.16%$3M60.0K
8BIIBBIOGEN INChistory →COM2.08%$3M11.0K
9BMY-RBMY CVR RTS 03/31/21history →RIGHT1.81%$3M1.21M
10KPTIEURKARYOPHARM THERAPEUTICS INChistory →COM1.64%$2M168.0K
11XLRNACCELERON PHARMA INChistory →COM1.40%$2M18.7K
12SOLENO THERAPEUTICS INCCOM1.39%$2M826.9K
13OXFORD IMMUNOTEC GLOBAL PLCCOM1.33%$2M170.3K
14BDQMALBIREO PHARMA INChistory →COM1.29%$2M58.0K
15MASI*MASIMO CORPhistory →COM1.26%$2M8.0K
16UTHUNITED THERAPEUTICS CORPhistory →COM1.21%$2M18.0K
17ARNAEURARENA PHARMACEUTICALS INChistory →COM1.10%$2M22.0K
18CCXIEURCHEMOCENTRYX INChistory →COM1.10%$2M30.0K
19MYOKEURMYOKARDIA INCCOM0.91%$1M10.0K
20CFRXEURCONTRAFECT CORPCOM0.90%$1M255.7K
21AMARIN CORP PLCSPONS ADR NEW0.84%$1M300.0K
22ETRNUSDEQUITRANS MIDSTREAM CORPORATIOCOM0.75%$1M133.1K
23HROWHARROW HEALTH INCCOM0.67%$1M180.0K
24HTDCORCEPT THERAPEUTICS INCCOM0.58%$870,00050.0K
25EPZMEUREPIZYME INCCOM0.56%$835,00070.0K
26VNDAVANDA PHARMACEUTICALS INCCOM0.52%$773,00080.0K
27IMGNEURIMMUNOGEN INCCOM0.46%$684,000190.0K
28STOKSTOKE THERAPEUTICS INCCOM0.45%$670,00020.0K
29BIOHAVEN PHARMACEUTICAL HOLDING CO LTDCOM0.43%$650,00010.0K
30AM6AMICUS THERAPEUTICS INCCOM0.36%$537,00038.0K
31INARI MEDICAL INCCOM0.32%$483,0007.0K
32XNCRXENCOR INCCOM0.32%$477,00012.3K
33CLRUSDCONTINENTAL RESOURCES INCCOM0.32%$474,00038.6K
34GTHXEURG1 THERAPEUTICS INCCOM0.31%$462,00040.0K
35PGNYPROGYNY INCCOM0.29%$441,00015.0K
36TRANSLATE BIO INCCOM0.27%$408,00030.0K
37TGTXTG THERAPEUTICS INCCOM0.27%$401,00015.0K
384XC1KALVISTA PHARMACEUTICALS INCCOM0.25%$378,00030.0K
39ARVNARVINAS INCCOM0.24%$354,00015.0K
40ICPTUSDINTERCEPT PHARMACEUTICALS INCCOM0.23%$344,0008.3K
41PXDEURPIONEER NATURAL RESOURCES COCOM0.22%$327,0003.8K
42VYGRVOYAGER THERAPEUTICS INCCOM0.21%$320,00030.0K
43INFLARX NVCOM0.20%$298,00070.0K
44OVVOVINTIV INCCOM0.19%$280,00034.4K
45ODONATE THERAPEUTICS INCCOM0.18%$269,00020.0K
46APLSUSDAPELLIS PHARMACEUTICALS INCCOM0.16%$241,0008.0K
47WKHSEURWORKHORSE GROUP INCCOM0.13%$202,0008.0K
48DRNAUSDDICERNA PHARMACEUTICALS INCCOM0.12%$180,00010.0K
49YIELD10 BIOSCIENCE INCCOM0.10%$147,00019.0K
50BCRXBIOCRYST PHARMACEUTICALS INCCOM0.05%$69,00020.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$176M73May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$171M68Feb 13, 202613F-HRchanges · EDGAR ↗
Q3 2025$132M69Nov 13, 202513F-HRchanges · EDGAR ↗
Q2 2025$101M71Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$115M68May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$123M68Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$115M62Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$108M61Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$122M60May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$128M59Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$117M52Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023Under review54Aug 8, 202313F-HRchanges · EDGAR ↗
Q1 2023$127,72555May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022Under review57Feb 3, 202313F-HRchanges · EDGAR ↗
Q3 2022$142M60Nov 28, 2022RESTATEMENTchanges · EDGAR ↗
Q2 2022$137M64Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$139M63May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$155M67Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$147M64Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$167M62Aug 10, 202113F-HRchanges · EDGAR ↗
Q1 2021$168M54May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$174M48Feb 9, 202113F-HRchanges · EDGAR ↗
Q3 2020$150M50Nov 12, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$165M51Aug 10, 202013F-HRchanges · EDGAR ↗
Q1 2020$113M46May 12, 202013F-HRchanges · EDGAR ↗
Q4 2019$138M52Feb 12, 202013F-HRchanges · EDGAR ↗
Q3 2019$150M50Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019$164M54Aug 6, 201913F-HRchanges · EDGAR ↗
Q1 2019$160M54May 3, 201913F-HRchanges · EDGAR ↗
Q4 2018$106M52Feb 6, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.